Chondroitin in Transdermal Patch and Its Main Physical Properties

Iyan Sopyan; Moeljadi G Tedjasaputra; Saskia Rizky Utami; Marline Abdassah

doi:10.24198/ijpst.v1i1.10425

Chondroitin in Transdermal Patch and Its Main Physical Properties

Iyan Sopyan, Moeljadi G Tedjasaputra, Saskia Rizky Utami, Marline Abdassah

Abstrak

Chondroitin sulphate (CS) in oral dosage form has widely used to help manage osteoarthritis, but regret its bioavailability was very low at only 13%, It was due to the first passed effect in the liver and to avoid it CS is needed to be formulated into another forms of preparation like patch. This study was aimed to gure out in-vitro possibility of chondroitin sulphate (CS) to be formulated in a transdermal patch and characterized by its physical properties such as permeation profile through the Franz’s cell and partition coefficient studies. The study showed that 150 mg CS in transdermal patch given the constant permeation within 19 hours with the partition coefficient of 2.22. Based on the permeation profile and the partition coefficient study, the CS patch would become an effective preparation to be considered.

Keyword : Chondroitin Sulphate (CS), Transdermal patch, Permeation profile, Partition coefficient

Teks Lengkap:

PDF (English)

Referensi

Aggrawal G, Shanju D, Kumar SLH. Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone. 2013;39(1):39-50.

Arthritis Foundation. Osteoarthritis. 2007 [accessed at 16 Januari 2012]. Available at: www.arthritis.org/disease-center.php?disease_id=32&df=definition.

Lockwood, B. Nutraceuticals. 2nd ed. Manchester, UK: Pharmaceutical Press.; 2007.

Lauder RM. Chondroitin sulphate: A complex molecule with potential impacts on a wide range of biological systems. Complement Therapies Med. 2009;17:56-62.

Malavaki CJ, Asimakopoulou AP, Lamari FN, Theocharis AD, Tzanakakis GN. Karamanos NK. Capillary electrophoresis for the quality control of chondroitin sulfates in raw materials and formulations. Anal Biochem. 2008;374:213-220.

Medlineplus. Joint Health and Care: Prevention, Symptoms, Diagnosis & Treatment. 2016. [accessed at 2 November 2016]. Available at https://medlineplus.gov/magazine/issues/ spring09/articles/spring09pg14.html.

Salerno C, Carlucci AM, Bregni C. Study of in vitro drug release and percutaneous absorption of fluconazole from topical dosage forms. AAPS Pharm. Sci. Tech. 2010;11(2):986–993.

Nice. Guidance on osteoarthritis. 2007. [Accessed at 3 November 2016]. Available at http://www.nice.org.uk/ cg59.

Rak J, Dejlová B, Lampová H, Kaplánek R, Matějíček P, Cígler P, et al. On the solubility and lipophilicity of metallacarborane pharmacophores. Mol. Pharm. 2013;10(5):1751–1759.

Schleindlin S. Transdermal Drug Delivery: Past, Present, Future. Molecular interventions. Pharm. Pharmacol. 2004;4(6):308-312.

Tan T. 2008. Kondroitin. [accessed at 11 Feb 2012]. Available at: http:// www.painrelief.com.sg/id/category/ chondroitin.html.

Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK. et al. OARSI recommendations for the management of hip and knee osteoarthritis Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010;18(4):476-499.

Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N. et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008:16;137-162.

DOI: https://doi.org/10.24198/ijpst.v1i1.10425